Bio-Gene Technology (ASX:BGT) Shares Rise: What's Happening Today?

Sonal Goyal

13 November 2026 01:19 PM AEDT

Bio-Gene Technology (ASX:BGT) Shares Rise: What's Happening Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Bio-Gene Technology shares were trading at $0.016 during the 13 November 2026 session, up 6.67%.
Documentation and product development are under way to support the first commercial Supply of Qcide to Japan.
Placement and share purchase plan proceeds totalled about $3.275 million, and a $343,000 R&D tax incentive was received after quarter end.

During the Trading session on 13 November 2026, Bio-Gene Technology Ltd (ASX:BGT) shares were trading at $0.016, up 6.67%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Bio-Gene is an Australian agtech company developing natural insecticides. Its latest update was its quarterly activities report and Appendix 4C for the quarter ended 30 September 2026, released on 30 October 2026.

Qcide commercial supply to Japan

Bio-Gene said documentation and product development activities are in progress to support the first commercial supply of Qcide to Japan. A 16th Qcide harvest was completed at its north Queensland plantation. Its managing director and chief executive attended major meetings in Japan and the United States during the quarter.

Toxicity studies and product validation

Draft preliminary reports for the OECD 424 and OECD 443 toxicity studies are under scientific and technical review before the results are finalised and released. After quarter end, efficacy data for Flavocide against ticks was published in the peer-reviewed Journal Ticks and Tick-borne Diseases. Grants and allowances were also obtained for Flavocide Patent families covering combinations, resistant pests and aphid control.

Funding and tax incentive

The company completed its second Tranche of the Placement and share purchase plan underwriting, bringing gross proceeds to about $3.275 million. It also received a $343,000 R&D tax incentive after quarter end, relating to eligible FY26 expenditure.

Sector context

Biological and plant-derived pest control products are seeking a place in agriculture as growers look for alternatives to conventional chemicals. Regulatory data, toxicity studies and product registrations in each export market are needed before commercial supply, and timelines can be long.

Risks investors are watching

Commercial supply to Japan depends on finalising documentation and regulatory steps that are still in progress. The toxicity study results are not yet final, and any findings could affect product development. The company's funding was raised at a low share price, and further Capital will be required to build commercial volumes.

What to watch ahead

Investors will look for the finalised OECD study results, the first commercial shipment of Qcide to Japan and progress on the Flavocide patents. The next Quarterly Report will show cash use and product development milestones.

Final Word

Bio-Gene's latest quarterly report centres on preparing a first commercial supply and completing product validation work. Regulatory and study milestones will show how quickly the product moves toward customers.

FAQs

Q: What is Bio-Gene preparing to do with Qcide?

A: The company is preparing documentation and product development to support the first commercial supply of Qcide to Japan.

Q: How much did the placement and share purchase plan raise?

A: Gross proceeds from the placement and share purchase plan totalled about $3.275 million.

Q: What studies are being reviewed?

A: Draft preliminary reports for the OECD 424 and OECD 443 toxicity studies are under scientific and technical review.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.